These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 30325535)

  • 1. Ferritin heavy/light chain (FTH1/FTL) expression, serum ferritin levels, and their functional as well as prognostic roles in acute myeloid leukemia.
    Bertoli S; Paubelle E; Bérard E; Saland E; Thomas X; Tavitian S; Larcher MV; Vergez F; Delabesse E; Sarry A; Huguet F; Larrue C; Bosc C; Farge T; Sarry JE; Michallet M; Récher C
    Eur J Haematol; 2019 Feb; 102(2):131-142. PubMed ID: 30325535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive analysis of ferritin subunits expression and positive correlations with tumor-associated macrophages and T regulatory cells infiltration in most solid tumors.
    Hu ZW; Chen L; Ma RQ; Wei FQ; Wen YH; Zeng XL; Sun W; Wen WP
    Aging (Albany NY); 2021 Apr; 13(8):11491-11506. PubMed ID: 33864445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Significance of Serum Ferritin at Diagnosis in Patients With Acute Myeloid Leukemia: A YACHT Multicenter Retrospective Study.
    Tachibana T; Andou T; Tanaka M; Ito S; Miyazaki T; Ishii Y; Ogusa E; Koharazawa H; Takahashi H; Motohashi K; Aoki J; Nakajima Y; Matsumoto K; Hagihara M; Hashimoto C; Taguchi J; Fujimaki K; Fujita H; Fujisawa S; Kanamori H; Nakajima H;
    Clin Lymphoma Myeloma Leuk; 2018 Jun; 18(6):415-421. PubMed ID: 29673622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Iron loading-induced aggregation and reduction of iron incorporation in heteropolymeric ferritin containing a mutant light chain that causes neurodegeneration.
    Muhoberac BB; Baraibar MA; Vidal R
    Biochim Biophys Acta; 2011 Apr; 1812(4):544-8. PubMed ID: 21029774
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MN1, FOXP1 and hsa-miR-181a-5p as prognostic markers in acute myeloid leukemia patients treated with intensive induction chemotherapy and autologous stem cell transplantation.
    Seipel K; Messerli C; Wiedemann G; Bacher U; Pabst T
    Leuk Res; 2020 Feb; 89():106296. PubMed ID: 31927137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The lincRNA HOTAIRM1, located in the HOXA genomic region, is expressed in acute myeloid leukemia, impacts prognosis in patients in the intermediate-risk cytogenetic category, and is associated with a distinctive microRNA signature.
    Díaz-Beyá M; Brunet S; Nomdedéu J; Pratcorona M; Cordeiro A; Gallardo D; Escoda L; Tormo M; Heras I; Ribera JM; Duarte R; de Llano MP; Bargay J; Sampol A; Nomdedeu M; Risueño RM; Hoyos M; Sierra J; Monzo M; Navarro A; Esteve J;
    Oncotarget; 2015 Oct; 6(31):31613-27. PubMed ID: 26436590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group.
    Gaidzik VI; Paschka P; Späth D; Habdank M; Köhne CH; Germing U; von Lilienfeld-Toal M; Held G; Horst HA; Haase D; Bentz M; Götze K; Döhner H; Schlenk RF; Bullinger L; Döhner K
    J Clin Oncol; 2012 Apr; 30(12):1350-7. PubMed ID: 22430270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-level expression of SAMHD1 in acute myeloid leukemia (AML) blasts correlates with improved outcome upon consolidation chemotherapy with high-dose cytarabine-based regimens.
    Rassidakis GZ; Herold N; Myrberg IH; Tsesmetzis N; Rudd SG; Henter JI; Schaller T; Ng SB; Chng WJ; Yan B; Ng CH; Ravandi F; Andreeff M; Kantarjian HM; Medeiros LJ; Xagoraris I; Khoury JD
    Blood Cancer J; 2018 Oct; 8(11):98. PubMed ID: 30341277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hyperferritinemia at diagnosis predicts relapse and overall survival in younger AML patients with intermediate-risk cytogenetics.
    Lebon D; Vergez F; Bertoli S; Harrivel V; De Botton S; Micol JB; Marolleau JP; Récher C
    Leuk Res; 2015 Aug; 39(8):818-21. PubMed ID: 26002512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of mitochondrial genes predicts survival in pediatric acute myeloid leukemia.
    Tyagi A; Pramanik R; Bakhshi R; Singh A; Vishnubhatla S; Bakhshi S
    Int J Hematol; 2019 Aug; 110(2):205-212. PubMed ID: 31119613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dexamethasone in hyperleukocytic acute myeloid leukemia.
    Bertoli S; Picard M; Bérard E; Griessinger E; Larrue C; Mouchel PL; Vergez F; Tavitian S; Yon E; Ruiz J; Delabesse E; Luquet I; Linares LK; Saland E; Carroll M; Danet-Desnoyers G; Sarry A; Huguet F; Sarry JE; Récher C
    Haematologica; 2018 Jun; 103(6):988-998. PubMed ID: 29519869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Value of Ferritin Heavy Chain (FTH1) Expression in Diagnosis and Prognosis of Renal Cell Carcinoma.
    Huang H; Qiu Y; Huang G; Zhou X; Zhou X; Luo W
    Med Sci Monit; 2019 May; 25():3700-3715. PubMed ID: 31104064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AML: high serum ferritin at initial diagnosis has a negative impact on long-term survival.
    Ihlow J; Gross S; Sick A; Schneider T; Flörcken A; Burmeister T; Türkmen S; Arnold R; Dörken B; Westermann J
    Leuk Lymphoma; 2019 Jan; 60(1):69-77. PubMed ID: 29846127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low miR-192 expression predicts poor prognosis in pediatric acute myeloid leukemia.
    Tian C; Zhang L; Li X; Zhang Y; Li J; Chen L
    Cancer Biomark; 2018; 22(2):209-215. PubMed ID: 29689705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myeloid-specific ferritin light chain deletion does not exacerbate sepsis-associated AKI.
    Odum JD; Akhter J; Verma V; Vollmer G; Davidson A; Hyndman KA; Bolisetty S
    Am J Physiol Renal Physiol; 2024 Jul; 327(1):F171-F183. PubMed ID: 38779751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Copy-number analysis identified new prognostic marker in acute myeloid leukemia.
    Nibourel O; Guihard S; Roumier C; Pottier N; Terre C; Paquet A; Peyrouze P; Geffroy S; Quentin S; Alberdi A; Abdelali RB; Renneville A; Demay C; Celli-Lebras K; Barbry P; Quesnel B; Castaigne S; Dombret H; Soulier J; Preudhomme C; Cheok MH
    Leukemia; 2017 Mar; 31(3):555-564. PubMed ID: 27686867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug responsiveness of leukemic cells detected in vitro at diagnosis correlates with therapy response and survival in patients with acute myeloid leukemia.
    Kolesnikova MA; Sen'kova AV; Pospelova TI; Zenkova MA
    Cancer Rep (Hoboken); 2021 Aug; 4(4):e1362. PubMed ID: 33675187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A 4-gene expression prognostic signature might guide post-remission therapy in patients with intermediate-risk cytogenetic acute myeloid leukemia.
    Torrebadell M; Díaz-Beyá M; Kalko SG; Pratcorona M; Nomdedeu J; Navarro A; Gel B; Brunet S; Sierra J; Camós M; Esteve J
    Leuk Lymphoma; 2018 Oct; 59(10):2394-2404. PubMed ID: 29390924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High Expression of VAV Gene Family Predicts Poor Prognosis of Acute Myeloid Leukemia.
    Mu D; Long S; Guo L; Liu W
    Technol Cancer Res Treat; 2021; 20():15330338211065877. PubMed ID: 34894858
    [No Abstract]   [Full Text] [Related]  

  • 20. Gene expression profiling of acute myeloid leukemia samples from adult patients with AML-M1 and -M2 through boutique microarrays, real-time PCR and droplet digital PCR.
    Handschuh L; Kaźmierczak M; Milewski MC; Góralski M; Łuczak M; Wojtaszewska M; Uszczyńska-Ratajczak B; Lewandowski K; Komarnicki M; Figlerowicz M
    Int J Oncol; 2018 Mar; 52(3):656-678. PubMed ID: 29286103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.